UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat

Drug metabolism and disposition, 1999-07, Vol.27 (7), p.827

1999

Volltextzugriff (PDF)

P-glycoprotein-mediated transport of morphine in brain capillary endothelial cells

Biochemical pharmacology, 1999-09, Vol.58 (6), p.951-957

1999

Volltextzugriff (PDF)

Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat

Pharmaceutical research, 1998-04, Vol.15 (4), p.599-605

1998

Volltextzugriff (PDF)

Increased brain P-glycoprotein in morphine tolerant rats

Life sciences (1973), 1999-12, Vol.66 (4), p.PL47-PL51

1999

Volltextzugriff (PDF)

PII-70

Clinical pharmacology and therapeutics, 2006-02, Vol.79 (2), p.P54-P54

2006

Volltextzugriff (PDF)

Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients

Anti-cancer drugs, 1998-08, Vol.9 (7), p.611-619

1998

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine S-1 on a Once-Daily-for-28-Day Schedule in Patients with Advanced Malignancies

Clinical cancer research, 2004-08, Vol.10 (15), p.4913-4921

2004

Volltextzugriff (PDF)

First-in-human study of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-00299804, a small molecule irreversible panHER inhibitor in patients with advanced cancer

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.3599-3599

2007

Volltextzugriff (PDF)

PI-13

Clinical pharmacology and therapeutics, 2006-02, Vol.79 (2), p.P10-P10

2006

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Once Daily Oral Administration of S-1 in Patients with Advanced Cancer

Clinical cancer research, 2002-07, Vol.8 (7), p.2116-2122

2002

Volltextzugriff (PDF)

Increased brain P-glycoprotein in morphine tolerant rats

Life sciences (1973), 2000-01, Vol.66 (4), p.PL47-PL51

2000

Volltextzugriff (PDF)

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2012-09, Vol.30 (27), p.3337-3344

2012

Volltextzugriff (PDF)

Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors

Clinical cancer research, 2011-06, Vol.17 (11), p.3841-3849

2011

Volltextzugriff (PDF)

Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3082-3082

2023

Volltextzugriff (PDF)

Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib: A Phase I/II Trial

Journal of thoracic oncology, 2014-10, Vol.9 (10), p.1523-1531

2014

Volltextzugriff (PDF)

randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer

Cancer chemotherapy and pharmacology, 2009-11, Vol.64 (6), p.1139-1148

2009

Volltextzugriff (PDF)

First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors

Clinical cancer research, 2007-02, Vol.13 (4), p.1238-1245

2007

Volltextzugriff (PDF)

Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors

Cancer chemotherapy and pharmacology, 2007-11, Vol.60 (6), p.799-809

2007

Volltextzugriff (PDF)

Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety

Cancer chemotherapy and pharmacology, 2008-06, Vol.62 (1), p.97-109

2008

Volltextzugriff (PDF)

Phase III randomized, open label study (ARCHER 1050) of first-line dacomitinib (D) versus gefitinib (G) for advanced (adv) non-small cell lung cancer (NSCLC) in patients (pts) with epidermal growth factor receptor ( EGFR ) activating mutation(s)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.TPS8123-TPS8123

2013

Volltextzugriff (PDF)

First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR -mutant lung cancers

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.7530-7530

2012

Volltextzugriff (PDF)

ARCHER: Dacomitinib (D; PF-00299804) versus erlotinib (E) for advanced (adv) non-small cell lung cancer (NSCLC)—A randomized double-blind phase III study

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.TPS7615-TPS7615

2012

Volltextzugriff (PDF)

PI-13Pharmacokinetics and pharmacodynamics of a HER2 tyrosine kinase inhibitor CP-724714 in patients with advanced malignant HER2 positive solid tumors

Clinical pharmacology and therapeutics, 2006-02, Vol.79 (2), p.P10-P10

2006

Volltextzugriff (PDF)

Evaluation of a novel RNA biomarker of CDK2 inhibition in phase 1 clinical trials with BMS-387032

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.2031-2031

2004

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(26)

Sprache

Englisch
(26)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat

P-glycoprotein-mediated transport of morphine in brain capillary endothelial cells

Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat

Increased brain P-glycoprotein in morphine tolerant rats

PII-70

Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients

Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine S-1 on a Once-Daily-for-28-Day Schedule in Patients with Advanced Malignancies

First-in-human study of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-00299804, a small molecule irreversible panHER inhibitor in patients with advanced cancer

PI-13

Phase I and Pharmacokinetic Study of Once Daily Oral Administration of S-1 in Patients with Advanced Cancer

Increased brain P-glycoprotein in morphine tolerant rats

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors

Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors

A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib

Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib: A Phase I/II Trial

randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer

First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors

Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors

Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety

Phase III randomized, open label study (ARCHER 1050) of first-line dacomitinib (D) versus gefitinib (G) for advanced (adv) non-small cell lung cancer (NSCLC) in patients (pts) with epidermal growth factor receptor ( EGFR ) activating mutation(s)

First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR -mutant lung cancers

ARCHER: Dacomitinib (D; PF-00299804) versus erlotinib (E) for advanced (adv) non-small cell lung cancer (NSCLC)—A randomized double-blind phase III study

PI-13Pharmacokinetics and pharmacodynamics of a HER2 tyrosine kinase inhibitor CP-724714 in patients with advanced malignant HER2 positive solid tumors

Evaluation of a novel RNA biomarker of CDK2 inhibition in phase 1 clinical trials with BMS-387032

Suchergebnisse filtern